SEC Filing · SCHEDULE 13G/A
Repare Therapeutics Inc.
SEC Filing
Company context
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polq ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor.
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗